Verona Pharma price target raised to $160 from $76 at Piper Sandler

Piper Sandler significantly raised its price target for Verona Pharma (VRNA) to $160 from $76, reiterating an Overweight rating, driven by the strong performance and investor interest in its COPD drug OHTUVAYRE. The drug's dual bronchodilation and anti-inflammatory effects, coupled with competitor failures, reinforce its market position, with Street expectations for OHTUVAYRE to achieve blockbuster status by 2027 and peak sales potential of $3-5 billion. This bullish sentiment is echoed by other firms like Jefferies and Cantor Fitzgerald, who also raised price targets or maintained positive ratings, citing robust sales growth and the company's strategic market expansion, contributing to VRNA's over 528% stock surge in the past year.

Analysis

A strong consensus of bullish analyst sentiment is forming around Verona Pharma (VRNA), primarily driven by the successful launch and commercial trajectory of its chronic obstructive pulmonary disease (COPD) drug, OHTUVAYRE. Piper Sandler's significant price target increase to $160 from $76 reflects this optimism, which is substantiated by tangible sales figures; Jefferies reported that OHTUVAYRE's sales grew to $71 million in the first quarter of 2025 from $37 million in the previous quarter. This performance strengthens the Street's expectation for the drug to achieve blockbuster status by 2027, with peak sales estimates reaching between $3-5 billion. Verona's market position is further solidified by OHTUVAYRE's differentiated therapeutic profile, offering both bronchodilation and anti-inflammatory effects, and the recent clinical trial failure of a competitor's drug (itepekimab). This wave of positive analyst actions, including upward revisions from Jefferies, Cantor Fitzgerald, and H.C. Wainwright, has fueled the stock's more than 528% surge over the past year, elevating the company's valuation to $8.6 billion.

Key Decisions for Investors

• Given the strong analyst consensus and accelerating OHTUVAYRE sales, investors may view the stock as a core holding in the biotech sector, but should remain cognizant of the significant valuation increase following its 528% run-up.
• Monitor Verona's quarterly earnings for continued OHTUVAYRE sales momentum, as the ability to meet or exceed near-term forecasts, such as the $400 million in 2025 sales noted by Cantor Fitzgerald, is critical to justifying the current valuation.
• Pay close attention to company updates on its sales force expansion and direct-to-patient advertising effectiveness, as well as any progress on label expansion into new indications like bronchiectasis, which represents a key future growth catalyst.